Mercury Biopharmaceutical (ROCO:6932) Net Debt Paydown Yield % : 0.02% (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6932 Mercury Biopharmaceutical Corp ROCO:6932
25 GF Score
Price NT$5.67
GF Value NT$36.00
Valuation Possible Value Trap
! 1 Warning Sign
View Full Analysis

What is Mercury Biopharmaceutical Net Debt Paydown Yield %?

Mercury Biopharmaceutical ROCO:6932 25 Net Debt Paydown Yield % is 0.02% as of Jul. 27, 2026. GuruFocus rates ROCO:6932 with a GF Score™ of 25/100 and a GF Value™ of NT$36.00 (Possible Value Trap). The stock has 1 warning sign investors should review. Among 921 Drug Manufacturers companies, Mercury Biopharmaceutical ranks better than 57.22% on this metric.

Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt. As of today, Mercury Biopharmaceutical's Net Debt Paydown Yield % was 0.02%.


Mercury Biopharmaceutical  (ROCO:6932) Net Debt Paydown Yield % Explanation

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.

In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.

We calculating the TTM average debt by adding up the total debt, calculated by the sum of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation, in the trailing twelve months(TTM) divided by the counts of the total debt, accoring to the company's report frequency.


Mercury Biopharmaceutical Net Debt Paydown Yield % Related Terms


Mercury Biopharmaceutical Net Debt Paydown Yield % Historical Data

* Premium members only.

The historical data trend for Mercury Biopharmaceutical's Net Debt Paydown Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mercury Biopharmaceutical Net Debt Paydown Yield % Chart

Mercury Biopharmaceutical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Debt Paydown Yield %
Get a 7-Day Free Trial 0.00 -1.03 0.01 -0.04 0.01

Mercury Biopharmaceutical Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Debt Paydown Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.02 -0.04 -0.12 0.01

ROCO:6932 vs ZTS: Net Debt Paydown Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Mercury Biopharmaceutical's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Mercury Biopharmaceutical Net Debt Paydown Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Mercury Biopharmaceutical's Net Debt Paydown Yield % distribution charts can be found below:

* The bar in red indicates where Mercury Biopharmaceutical's Net Debt Paydown Yield % falls into.


ROCO:6932
25GF Score
Mercury Biopharmaceutical Corp ROCO:6932
Net Debt Paydown Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mercury Biopharmaceutical Net Debt Paydown Yield % Calculation

Mercury Biopharmaceutical's Net Debt Paydown Yield % for the quarter that ended in Dec. 2025 is calculated as:

Net Debt Paydown Yield %
=( TTM Average Debt   (1-Year Ago))-TTM Average Debt )/Market Cap
=( 44.73-44.32 )/3470.16384
=0.01 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

What does a Net Debt Paydown Yield % of 0.02% mean?
Mercury Biopharmaceutical (ROCO:6932) has a Net Debt Paydown Yield % of 0.02% as of Jul. 27, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Mercury Biopharmaceutical and its competitors. According to the industry distribution chart, Mercury Biopharmaceutical ranks #394 out of 921 companies in the Drug Manufacturers industry, placing it in the top 42.8%.
Is Mercury Biopharmaceutical's Net Debt Paydown Yield % too high?
Mercury Biopharmaceutical's current Net Debt Paydown Yield % is 0.02%. Based on the distribution chart, Mercury Biopharmaceutical ranks #394 out of 921 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Mercury Biopharmaceutical has a GF Score™ of 25/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Mercury Biopharmaceutical's Net Debt Paydown Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Mercury Biopharmaceutical ranks #394 out of 921 companies for Net Debt Paydown Yield %. This puts Mercury Biopharmaceutical in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Drug Manufacturers company?
A good Net Debt Paydown Yield % depends on the Drug Manufacturers industry context. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Mercury Biopharmaceutical and its competitors. Mercury Biopharmaceutical's current Net Debt Paydown Yield % is 0.02%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mercury Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Mercury Biopharmaceutical (ROCO:6932) is currently considered Possible Value Trap. The stock's GF Value™ is NT$36.00, compared to a current price of NT$5.67 — trading 84.3% below its estimated fair value. The current Net Debt Paydown Yield % is 0.02%. Mercury Biopharmaceutical's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Mercury Biopharmaceutical (ROCO:6932), the current Net Debt Paydown Yield % is 0.02% as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mercury Biopharmaceutical (ROCO:6932) Overvalued in 2026?

Based on GuruFocus' analysis, Mercury Biopharmaceutical stock appears to be undervalued. The current stock price of NT$5.67 is trading 84.3% below its estimated GF Value™ of NT$36.00. GuruFocus considers Mercury Biopharmaceutical to be Possible Value Trap.

Key valuation signals for ROCO:6932:

  • Net Debt Paydown Yield %: 0.02%
  • GF Value™: NT$36.00 vs. price of NT$5.67 (84.3% below fair value)
  • GF Score™: 25/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6932 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mercury Biopharmaceutical Business Description

Address No. 653-1, Bannan Road, 15th Floor, Zhonghe District, New Taipei City, TWN
Mercury Biopharmaceutical Corp focuses on the development of drugs for unmet medical needs. It offers a development platform focusing on rapid release and free adjustable doses. Its 3D powder bonding method (binder jetting) combines powder and special molding adhesive and stacks them in layers.
25GF Score

Get the complete analysis for ROCO:6932

Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$5.67
Price
NT$36.00
GF Value